Veteran Pakistan wicketkeeper-batsman Kamran Akmal has come out in defence of his younger brother Umar, who is facing a ban for allegedly misbehaving at a fitness test, saying he was just joking and didn't intend to offend anyone.
Out-of-favour Umar, who has a history of landing himself in controversies, apparently made some crude remarks to a trainer when the skin-folding test was being conducted at the National Cricket Academy.
The matter has been reported to the Pakistan Cricket Board (PCB) and Umar now faces the prospect of being banned from the country's next domestic tournament.
"Umar and Yasir (the trainer) have studied together and are friends so I think whatever Umar said was in a lighter mood and he didn't have any intention to misbehave with anyone," Kamran said on the Gsports show on GTV News Channel.
Kamran too finds himself in a spot of bother with the Pakistan Cricket Board (PCB) after he skipped two fitness tests and failed when he finally appeared for the test.
The two brothers remain out of favour with the national selectors and a source said that the matter had been brought to the notice of the PCB which was now conducting an inquiry and would take appropriate action.
"Umar could find himself banned from playing in the coming national one-day championship," the source said.
Kamran said they know the importance of maintaining high fitness standards and were working hard on their fitness levels to meet the new required standards set by the Pakistan team management.
"But as usual this incident has been overblown in the media. Because Umar didn't do anything intentionally. He was just joking," said Kamran, who last played for Pakistan in 2017 in the West Indies.
"But if the PCB feels in its inquiry he has done something wrong they should caution and reprimand him. He can also apologize but a ban would be very harsh," he said.
About his failing the fitness test, Kamran said he had been playing cricket for the last 20-years and had always given his best on the field.
"Even this season I have constantly played in the Quaid-e-Azam Trophy and the national T20 championship without any problems with my match fitness and I have also performed well," said the 38-year-old.
"I just think nowadays there is over stress on fitness rather than on improving match skills of players," added Kamran, who has played 53 Tests, 157 ODIs and 58 T20 internationals for Pakistan.
Kamran, 38, said that the players should be given a chance to prepare for this tests.
"But I or Umar have no issues with trying to meet the new fitness standards. The new tests are pretty tough for anyone so I think players must be given a chance to prepare for these tests.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.